九洲药业: 浙江九洲药业股份有限公司关于控股子公司获得药品注册证书的公告

Group 1 - The company Zhejiang Jiuzhou Pharmaceutical Co., Ltd. announced that its subsidiary Zhejiang Jiuzhou Biopharmaceutical Co., Ltd. received a drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets from the National Medical Products Administration [1][2] - The drug is classified as a chemical drug of category 4, with a specification of 50mg and a registration number valid until June 23, 2030 [1] - The total sales of Sildenafil Citrate tablets in the domestic medical and retail market reached 5.217 billion RMB in 2023 [2] Group 2 - The approval of the drug registration certificate enhances the company's product pipeline and market competitiveness [2] - The company has invested approximately 13.52 million RMB in the research and development of Sildenafil Citrate Orally Disintegrating Tablets [2]